Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Malvern, PA, US. The stock last traded at $1.89, up 0.00% on the session, giving a market capitalisation of $80.4M. On trailing twelve-month figures it carries a trailing P/E of -1.10, a net margin of 0.0%. Its beta of 1.24 implies it has historically moved more than the broad market.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Annovis Bio, Inc. is most often compared with the following Healthcare names: